

TG Therapeutics (NASDAQ:TGTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been...
You can purchase shares of TG Therapeutics (NASDAQ:TGTX) through any online brokerage.
Other companies in TG Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
TG Therapeutics has a consensus price target of $53.08.
The stock price for TG Therapeutics (NASDAQ: TGTX) is $66.0161 last updated November 19, 2026 at 4:43 PM EST.
There are no upcoming dividends for TG Therapeutics.
TG Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for TG Therapeutics.
TG Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval...